Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy

• Published in: The European respiratory journal Vol. 50; no. 3; p. 1700782
• Main Authors: Wortley, Michael A, Adcock, John J, Dubuis, Eric D, Maher, Sarah A, Bonvini, Sara J, Delescluse, Isabelle, Kinloch, Ross, McMurray, Gordon, Perros-Huguet, Christelle, Papakosta, Marianthi, Birrell, Mark A, Belvisi, Maria G
• Format: Journal Article
• Language: English
• Published: England European Respiratory Society Journals Ltd 01.09.2017
• Subjects: Adult; Aged; Amides; Amidohydrolases - antagonists & inhibitors; Analgesics; Anandamide; Animals; Antitussive Agents - therapeutic use; Aza Compounds - pharmacology; Calcium channels; Cannabinoid CB2 receptors; Cannabinoid Receptor Modulators - pharmacology; Cannabinoids - antagonists & inhibitors; Capsaicin - pharmacology; Cough; Cough - drug therapy; Electrophysiology; Enzyme Inhibitors - therapeutic use; Fatty acids; Fatty-acid amide hydrolase; Female; Guinea Pigs; Humans; Hydrolase; Inflammation; Male; Middle Aged; Oleic acid; Palmitoylethanolamide; Phosphoprotein phosphatase; Potassium channels; Primary care; Protein phosphatase; Receptor, Cannabinoid, CB2 - drug effects; Respiratory tract; Spiro Compounds - pharmacology; Vagus nerve; Vagus Nerve - drug effects

Cough is the most common reason to visit a primary care physician, yet it remains an unmet medical need. Fatty acid amide hydrolase (FAAH) is an enzyme that breaks down endocannabinoids, and inhibition of FAAH produces analgesic and anti-inflammatory effects. Cannabinoids inhibit vagal sensory nerve...